CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
2018 ◽
Vol 10
◽
pp. 175883591881834
◽
Keyword(s):
The development of cyclin-dependent kinase (CDK) 4/6 inhibitors has been more prominent in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, with a significant improvement in progression-free survival (PFS) in first and later lines of metastatic breast cancer (MBC) therapy. Preclinical evidence suggests that there is activity of CDK4/6 inhibitors in nonluminal cell lines. Here, we present a review of the current preclinical and clinical data on the use of CDK inhibitors in HER2-positive and triple-negative breast cancer (TNBC).
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS1107-TPS1107
◽
2018 ◽
Vol 25
(1)
◽
pp. 110-129
◽
2018 ◽
Vol 34
(9)
◽
pp. 1645-1652
◽
2021 ◽
Vol 39
(15_suppl)
◽
pp. 1040-1040
2009 ◽
Vol 27
(33)
◽
pp. 5538-5546
◽